Investment16 Feb 2026, 01:44 pm
Ind-Swift Laboratories to Invest ₹ 400 Million for EU-GMP & PIC/S Compliance, Aims ₹ 750-800 Million Sales from FY 27-28
AI Summary
Ind-Swift Laboratories Limited has approved a capital investment of approximately ₹ 400 million to upgrade its finished dosage manufacturing facility located at Samba, Jammu & Kashmir. The company aims to generate an overall sales of close to ₹ 750-800 million and a strong bottom line of 18-20% of revenues with this investment from FY 27-28 onwards. The upgradation is expected to improve process robustness, minimize manual intervention, reinforce data integrity, and ensure consistent high-quality output.
Key Highlights
- Ind-Swift to invest ₹ 400 million for EU-GMP & PIC/S compliance at Samba facility.
- Expected to complete the upgradation within 8-12 months and receive EU GMP approval within 8-9 months.
- Aims to generate ₹ 750-800 million sales and a strong bottom line of 18-20% of revenues from FY 27-28 onwards.
- Upgradation designed to future-proof the facility, enable scalable growth, elevate global compliance readiness, and reinforce patient safety.
- Ind-Swift witnessing increased demand for its products in the export markets.